In a given year, approximately 185,000 patients with sarcoidosis seek medical care in the U.S.1
In one study of 500 patients, 43% were being treated for persistent disease by 5 years after diagnosis.2
PulSar is a Phase 4 multicenter, randomized, double blind, placebo controlled pilot study to assess the efficacy and safety of Acthar® Gel in subjects with Pulmonary Sarcoidosis.
The study is designed to last for 24 weeks, with an optional open-label, 24 week extension period.
*Follow-up visit occurs 28 days after last dose of study drug
• Be between 18 and 90 years of age
• Have biopsy-confirmed sarcoidosis for >1 year prior to initial visit
• Be on a stable prednisone dose for at least 4 weeks prior to initial visit
*Other criteria are necessary to qualify for this study. Talk to your doctor about all qualifications.